Grifols, ES0171996087

Grifols stock falls 3.09 percent after index exits

Published on 09/25/2026 at 12:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Grifols stock reported first-half revenue of EUR 3.6 billion on July 28, 2026, up 2.6 percent at constant currency. Net profit rose 28.7 percent to EUR 227 million.

Isometrische 3D-Grafik der Plasma-Wertschöpfungskette von Spende bis Medikament — Isometrische 3D-Illustration zeigt die Wertschöpfungskette von der Plasmaspende bis zum Medikament bei Grifols S.A. ES0171996087, Illustration mit AI erstellt.

Grifols stock (ISIN ES0171996087) fell 3.09 percent to EUR 9.360 on BME on September 23, 2026. The move came as MarketScreener reported Grifols' removal from the S&P International 700 and the S&P Europe 350 pharmaceuticals, biotechnology and life sciences industry group on September 23, 2026. The index changes put the recent share-price weakness alongside a still improving operating picture.

Index exits meet stronger earnings

Grifols reported first-half 2026 revenue of EUR 3.6 billion, up 2.6 percent at constant currency. According to Grifols, the company released the figures on July 28, 2026, together with net profit of EUR 227 million, an increase of 28.7 percent.

The quarterly split shows why the half-year result matters. Revenue reached EUR 1.874 billion in Q2 2026, compared with EUR 1.700 billion in Q1, while consolidated net income rose from EUR 88 million to EUR 183 million. The figures indicate that earnings improved more quickly than revenue during the first half.

Biopharma supplies the growth

Biopharma was the main operating driver in the first half, with growth of 5.4 percent at constant currency, according to the company's July 28, 2026 release. That performance gives the business a concrete counterweight to the market's negative reaction to the index removals.

Cash generation also strengthened during the first half. Operating cash flow reached EUR 228 million in Q2 2026, compared with EUR 110 million in Q1, while cash and cash equivalents stood at EUR 513 million on June 30, 2026. The sequential cash-flow increase is an important financial marker because Grifols operates with a capital-intensive plasma collection and manufacturing network.

Stock trades below recent levels

Grifols stock stood at EUR 9.360 on BME on September 23, 2026, with a daily change of minus 3.09 percent. The same dated market snapshot reported a prior close of EUR 9.659. For investors, the central contrast is clear: first-half revenue and profit growth improved, while the index exits added short-term pressure to the share price.